Haiming Dai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2626510/publications.pdf

Version: 2024-02-01

218677 254184 2,036 50 26 43 h-index citations g-index papers 66 66 66 3315 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Therapeutics targeting BCL2 family proteins. , 2022, , 197-260.		3
2	BCL2L13: physiological and pathological meanings. Cellular and Molecular Life Sciences, 2021, 78, 2419-2428.	5.4	22
3	Crystal structure of the WD40 domain of human PLRG1. Biochemical and Biophysical Research Communications, 2021, 534, 474-477.	2.1	1
4	Enrichment and detection of circulating tumor cells by immunomagnetic beads and flow cytometry. Biotechnology Letters, 2021, 43, 25-34.	2,2	7
5	Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma. Cancer Cell International, 2021, 21, 332.	4.1	3
6	An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer. Frontiers in Immunology, 2021, 12, 704655.	4.8	5
7	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death and Disease, 2021, 12, 789.	6.3	4
8	Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. International Journal of Biological Sciences, 2021, 17, 4207-4222.	6.4	35
9	Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis. Cell Proliferation, 2020, 53, e12741.	5.3	27
10	Selective binding of mitophagy receptor protein Bcl-rambo to LC3/GABARAP family proteins. Biochemical and Biophysical Research Communications, 2020, 530, 292-300.	2.1	16
11	Selective Inhibition of BFL1: It's All about Finding the Right Partner. Cell Chemical Biology, 2020, 27, 639-642.	5.2	2
12	Characterization of an alternative BAK-binding site for BH3 peptides. Nature Communications, 2020, 11, 3301.	12.8	31
13	Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. Cell Death and Disease, 2020, 11, 281.	6.3	149
14	Identification of FPR3 as a Unique Biomarker for Targeted Therapy in the Immune Microenvironment of Breast Cancer. Frontiers in Pharmacology, 2020, 11 , 593247 .	3.5	9
15	Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. Scientific Reports, 2019, 9, 11677.	3.3	25
16	Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma. Molecular Therapy - Oncolytics, 2019, 14, 82-93.	4.4	35
17	DHHC protein family targets different subsets of glioma stem cells in specific niches. Journal of Experimental and Clinical Cancer Research, 2019, 38, 25.	8.6	44
18	Measurement of BH3-only protein tolerance. Cell Death and Differentiation, 2018, 25, 282-293.	11.2	27

#	Article	IF	CITATIONS
19	Fluorine Pseudocontact Shifts Used for Characterizing the Protein–Ligand Interaction Mode in the Limit of NMR Intermediate Exchange. Angewandte Chemie, 2017, 129, 13162-13166.	2.0	O
20	Fluorine Pseudocontact Shifts Used for Characterizing the Protein–Ligand Interaction Mode in the Limit of NMR Intermediate Exchange. Angewandte Chemie - International Edition, 2017, 56, 12982-12986.	13.8	23
21	Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. Oncotarget, 2017, 8, 106486-106498.	1.8	12
22	Mitochondrial apoptosis and BH3 mimetics. F1000Research, 2016, 5, 2804.	1.6	33
23	4EBP1/c-MYC/PUMA and NF-ήB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood, 2016, 127, 2711-2722.	1.4	49
24	Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. Journal of Virology, 2016, 90, 4032-4048.	3.4	85
25	BCL2 Family, Mitochondrial Apoptosis, and Beyond. Cancer Translational Medicine, 2016, 2, 7.	0.2	44
26	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood, 2015, 125, 658-667.	1.4	108
27	COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A. Molecular Biology of the Cell, 2015, 26, 91-103.	2.1	200
28	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1658-1671.	4.1	122
29	Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes and Development, 2015, 29, 2140-2152.	5.9	38
30	Cell Surface Protein Disulfide Isomerase Regulates Natriuretic Peptide Generation of Cyclic Guanosine Monophosphate. PLoS ONE, 2014, 9, e112986.	2.5	6
31	Evaluation of the BH3-only Protein Puma as a Direct Bak Activator. Journal of Biological Chemistry, 2014, 289, 89-99.	3.4	65
32	Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. Journal of Cell Biology, 2014, 206, 867-876.	5.2	28
33	Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis. Journal of Biological Chemistry, 2014, 289, 22835-22849.	3.4	47
34	CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of the Bcl-2 Family Members Bcl-XL, Noxa, and Bak. Journal of Biological Chemistry, 2013, 288, 22899-22914.	3.4	59
35	Contribution of Bcl-2 Phosphorylation to Bak Binding and Drug Resistance. Cancer Research, 2013, 73, 6998-7008.	0.9	81
36	Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. Scientific Reports, 2012, 2, 257.	3.3	41

#	Article	IF	Citations
37	High Cell Surface Death Receptor Expression Determines Type I Versus Type II Signaling*. Journal of Biological Chemistry, 2011, 286, 35823-35833.	3.4	27
38	Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood, 2011, 118, 4872-4881.	1.4	27
39	Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. Journal of Cell Biology, 2011, 194, 39-48.	5.2	139
40	Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells. Journal of Biological Chemistry, 2011, 286, 17682-17692.	3.4	80
41	Protein Kinase $\hat{Cl^2}$ Modulates Ligand-induced Cell Surface Death Receptor Accumulation. Journal of Biological Chemistry, 2010, 285, 888-902.	3.4	15
42	Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis. Journal of Biological Chemistry, 2009, 284, 18311-18322.	3.4	47
43	MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis. Journal of Biological Chemistry, 2007, 282, 29831-29846.	3.4	104
44	Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. Biochemical and Biophysical Research Communications, 2007, 358, 435-441.	2.1	54
45	Investigation of the four cooperative unfolding units existing in the MICAL-1 CH domain. Biophysical Chemistry, 2007, 129, 269-278.	2.8	7
46	Structure of human upstream binding factor HMG box 5 and site for binding of the cell-cycle regulatory factor TAF1. Acta Crystallographica Section D: Biological Crystallography, 2007, 63, 730-737.	2.5	8
47	2P060 Solution Structure of the Bromodomain of Brd2 and Its Interaction with Acetylated Peptide from Histone H4 and CtBP(29. Protein structure and dynamics (II),Poster Session,Abstract,Meeting) Tj ETQq1 1 (0. 78.4 314	rg & T /Overlo
48	Binding model of human coactosin-like protein with filament actin revealed by mutagenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 1688-1700.	2.3	18
49	Solution structure of calponin homology domain of Human MICAL-1. Journal of Biomolecular NMR, 2006, 36, 295-300.	2.8	18
50	Letter to the Editor:1H,13C and15N Resonance Assignments and the Secondary Structures of Human Coactosin Like Protein (hCLP) D123N. Journal of Biomolecular NMR, 2004, 29, 455-456.	2.8	5